

| | |
|---|-----------|
| OMB APPROVAL | |
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response: | 0.5 |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | |
|---|---|---|
| 1. Name and Address of Reporting Person* BRADBURY DANIEL (Last) (First) (Middle) C/O CASTLE BIOSCIENCES, INC. 820 S. FRIENDSWOOD DRIVE, SUITE 201 (Street) FRIENDSWOOD TX 77546 (City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol CASTLE BIOSCIENCES INC [CSTL] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input type="checkbox"/> Officer (give title below) Other (specify below) |
| | 3. Date of Earliest Transaction (Month/Day/Year) 07/29/2019 | |
| | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|-----------------------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock | 07/29/2019 | | C | | 837,575 ⁽¹⁾ | A | (2) | 837,575 | I | By LLC ⁽³⁾ |
| Common Stock | 07/29/2019 | | C | | 71,003 | A | \$12.8 ⁽⁴⁾ | 908,578 | I | By LLC ⁽³⁾ |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|-----------------------------|--|-----------------|---|----------------------------|--|--|---|--|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Series A Preferred Stock | (2) | 07/29/2019 | | C | | | 136,906 | (2) | (2) | Common Stock | 112,307 | (2) | 0 | I | By LLC ⁽³⁾ |
| Series B Preferred Stock | (2) | 07/29/2019 | | C | | | 157,059 | (2) | (2) | Common Stock | 128,839 | (2) | 0 | I | By LLC ⁽³⁾ |
| Series C Preferred Stock | (2) | 07/29/2019 | | C | | | 28,735 | (2) | (2) | Common Stock | 23,572 | (2) | 0 | I | By LLC ⁽³⁾ |
| Series D Preferred Stock | (2) | 07/29/2019 | | C | | | 171,798 | (2) | (2) | Common Stock | 140,932 | (2) | 0 | I | By LLC ⁽³⁾ |
| Series E-1 Preferred Stock | (2) | 07/29/2019 | | C | | | 168,528 | (2) | (2) | Common Stock | 138,250 | (2) | 0 | I | By LLC ⁽³⁾ |
| Series E-2 Preferred Stock | (2) | 07/29/2019 | | C | | | 54,613 | (2) | (2) | Common Stock | 44,801 | (2) | 0 | I | By LLC ⁽³⁾ |
| Series E-3 Preferred Stock | (2) | 07/29/2019 | | C | | | 48,584 | (2) | (2) | Common Stock | 39,855 | (2) | 0 | I | By LLC ⁽³⁾ |
| Series F Preferred Stock | (2) | 07/29/2019 | | C | | | 254,781 | (2) | (2) | Common Stock | 209,005 | (2) | 0 | I | By LLC ⁽³⁾ |
| Convertible Promissory Note | \$12.8 ⁽⁴⁾ | 07/29/2019 | | C | | | \$874,537.48 ⁽⁴⁾ | (4) | (4) | Common Stock | 71,003 | (4) | 0 | I | By LLC ⁽³⁾ |

Explanation of Responses:

- The shares of Common Stock issued upon conversion of the Preferred Stock were calculated by first aggregating all series of Preferred Stock held by the Reporting Person, in accordance with the terms of the Company's then-effective Certificate of Incorporation.
- Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.
- Held by BioBrit, LLC (the "LLC"), of which the Reporting Person is the managing member and has voting and investment power over the shares.
- The principal amount of the Convertible Promissory Note held by the LLC was \$874,537.48. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of \$16.00 per share.

Remarks:

/s/ Greg Acosta, Attorney-in-
fact

07/31/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.